Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re: Alfuzosin Hydrochloride Patent Litigation
Case Number:
1:08-md-01941
Court:
Nature of Suit:
Multi Party Litigation:
Multi-district Litigation
Judge:
Firms
- Carlton Fields
- Farnan LLP
- Morris James
- Morris Nichols
- Potter Anderson
- Richards Layton
- Shaw Keller
- Shook Hardy
- Young Conaway
Companies
- Allergan PLC
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Par Pharmaceutical Cos. Inc.
- Ranbaxy
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Wockhardt Ltd.
- Wockhardt USA LLC
Sectors & Industries:
-
January 14, 2011
Sanofi Beats Back Apotex Generic In Uroxatral MDL
A federal judge overseeing the multidistrict litigation arising from Sanofi-Aventis SA's prostate drug Uroxatral has held that the patent covering the treatment was valid and infringed by Apotex Inc.'s proposed generic copycat.
-
August 19, 2010
Aurobindo, Torrent Infringe Sanofi's Uroxatral IP: Judge
A federal judge has ruled that Sanofi-Aventis’ patent covering prostate treatment Uroxatral is valid and infringed by proposed generic versions from Aurobindo Pharma Ltd. and Torrent Pharma Inc.
-
May 17, 2010
Mylan Generic Infringes Sanofi's Uroxatral Patent: Judge
A federal judge has given Sanofi-Aventis SA a boost in its multidistrict litigation over competitors' attempts to market a generic version of prostate treatment Uroxatral, ruling at trial that the drug proposed by Mylan Pharmaceutical Inc. would in fact infringe Sanofi’s patent.
-
May 20, 2009
Sanofi Uroxatral Claim Construction Gets Judge's Nod
A federal judge has handed down a claim construction order for one of the patents in Sanofi-Aventis’ multidistrict litigation alleging Mylan Pharmaceuticals Inc. and other generic-drug manufacturers have infringed its technology covering its prostate treatment, Uroxatral.
-
June 13, 2008
Sanofi Asserts 2nd Uroxatral Patent Against Sun
Sanofi-Aventis has hit Sun Pharmaceutical Industries Ltd. with another patent infringement suit over the drug Uroxatral, alleging that the generics maker infringed another of its patents for the prostate treatment.